Global Digital Health For Obesity Market
Digital Health for Global Obesity Market Analysis Report 2024-2030, Featuring MyFitnessPal, Teladoc, FitnessKeeper, PlateJoy, Tempus, Fitbit, Noom, WellDoc, Sidekick Health and BioAge Labs
May 14, 2024 08:32 ET | Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Digital Health For Obesity Market Size, Share & Trends Analysis Report By Component (Hardware, Software, Services), By End-use (Patients, Providers,...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
May 14, 2024 07:57 ET | ZyVersa Therapeutics
To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.
Fractyl-Logo.png
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024 16:00 ET | Fractyl Health, Inc.
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Fractyl-Logo.png
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
May 08, 2024 06:00 ET | Fractyl Health, Inc.
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
Fractyl-Logo.png
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
May 07, 2024 06:00 ET | Fractyl Health, Inc.
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
800 px horizontal logo.png
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
May 02, 2024 08:30 ET | Elevai Labs Inc.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
800 px horizontal logo.png
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
May 01, 2024 09:00 ET | Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
22157.jpg
Global Anti-obesity Medication Market Trends Analysis Report 2024-2030: Social Media Influences and Strategic Partnerships, Mergers, Acquisitions, and Collaborations Shaping the Landscape
April 11, 2024 11:14 ET | Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Global Anti-obesity Medication Market Size, Share & Trends Analysis Report" report has been added to ResearchAndMarkets.com's offering.The global...
UMeWorld to Debut the World's First & Only Weight Loss Cooking Oil in the US
April 09, 2024 08:00 ET | UMeWorld Limited
MIAMI, April 09, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF) is excited to announce that the company has secured an exclusive license to use proprietary enzymatic technologies to...
Fractyl-Logo.png
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
April 02, 2024 08:00 ET | Fractyl Health, Inc.
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation